Immunotoxins: all 376 studies that test it

Page 2 of 4. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.

• A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a TaxaneCompletedNCT02658734Phase 4Results posted
• Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast CancerTerminatedNCT02658084Phase 1/2Results posted
• An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted
• Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaTerminatedNCT02594163Phase 2Results posted
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
• An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCompletedNCT02581631Phase 1/2Results posted
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted
• Dose Ranging Study of Brentuximab Vedotin in Adults With LupusTerminatedNCT02533570Phase 2Results posted
• Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin LymphomaCompletedNCT02505269Phase 2Results posted
• Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial SarcomaCompletedNCT02452554Phase 2Results posted
• Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02429375Phase 1/2Results posted
• A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCLCompletedNCT02423291Phase 2Results posted
• An Open-label Phase II Study of Lorvotuzumab MertansineCompletedNCT02420873Phase 2Results posted
• Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive LymphomasCompletedNCT02388490Phase 2Results posted
• T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingNCT02326974Phase 2Results posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02289833Phase 2Results posted
• A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerCompletedNCT02236000Phase 1/2Results posted
• Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02227199Phase 1/2Results posted
• Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaTerminatedNCT02227108Phase 2Results posted
• Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast CancerActive, not recruitingNCT02226276Not applicableResults posted
• Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)TerminatedNCT02169505Phase 2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaActive, not recruitingNCT02166463Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast CancerTerminatedNCT02144012Phase 3Results posted
• A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT02131064Phase 3Results posted
• Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
• BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane TxCompletedNCT02038010Phase 1Results posted
• Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma PatientsCompletedNCT01994850Phase 1/2Results posted
• A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 4Results posted
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaCompletedNCT01979536Phase 2Results posted
• A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerCompletedNCT01966471Phase 3Results posted
• A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
• Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT01925612Phase 2Results posted
• S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01925131Phase 1Results posted
• Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaActive, not recruitingNCT01920932Phase 2Results posted
• Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
• Cardiac Safety Study in Patients With HER2 + Breast CancerCompletedNCT01904903Phase 2Results posted
• Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaCompletedNCT01874054Phase 1/2Results posted
• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)CompletedNCT01853748Phase 2Results posted
• Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30TerminatedNCT01841021Not applicableResults posted
• Moxetumomab Pasudotox for Advanced Hairy Cell LeukemiaCompletedNCT01829711Phase 3Results posted
• Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT01807598Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01780662Phase 1/2Results posted
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasCompletedNCT01777152Phase 3Results posted
• A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)CompletedNCT01772472Phase 3Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaCompletedNCT01771107Phase 1/2Results posted
• A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaCompletedNCT01712490Phase 3Results posted
• A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentCompletedNCT01702571Phase 3Results posted
• Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia TreatmentCompletedNCT01698879Phase 2Results posted
• Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing ChemotherapyCompletedNCT01679119Phase 2Results posted
• CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCompletedNCT01664910Phase 1/2Results posted
• Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)CompletedNCT01657331Phase 1/2Results posted
• A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Phase 2/3Results posted
• Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin LymphomaCompletedNCT01578967Not applicableResults posted
• A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3Results posted
• A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaCompletedNCT01564784Phase 3Results posted
• Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin LymphomaCompletedNCT01534078Phase 2Results posted
• Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01508312Phase 2Results posted
• HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesCompletedNCT01494662Phase 2Results posted
• Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin LymphomaCompletedNCT01476410Phase 2Results posted
• Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesCompletedNCT01461538Phase 2Results posted
• A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed TherapyCompletedNCT01419197Phase 3Results posted
• Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression LevelCompletedNCT01396070Phase 2Results posted
• Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin LymphomaCompletedNCT01393717Phase 2Results posted
• Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic LeukemiaCompletedNCT01363297Phase 2Results posted
• A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung CancerTerminatedNCT01237678Phase 1/2Results posted
• A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyTerminatedNCT01232556Phase 3Results posted
• A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast CancerCompletedNCT01196052Phase 2Results posted
• CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)CompletedNCT01134575Phase 2Results posted
• A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)CompletedNCT01120184Phase 3Results posted
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)CompletedNCT01100502Phase 3Results posted
• Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's LymphomaCompletedNCT01055496Phase 1Results posted
• Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)CompletedNCT01030536Phase 1/2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00968071Phase 2Results posted
• A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudyCompletedNCT00947856Phase 2Results posted
• Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease ProgressionCompletedNCT00943670Phase 2Results posted
• A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing RegimenCompletedNCT00932373Phase 1Results posted
• Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCompletedNCT00895934Phase 1/2Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)CompletedNCT00882102Phase 2Results posted
• A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received TrastuzumabCompletedNCT00875979Phase 1/2Results posted
• Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins LymphomaCompletedNCT00868608Phase 2Results posted
• Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00867087Phase 2Results posted
• A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaCompletedNCT00866047Phase 2Results posted
• A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin LymphomaCompletedNCT00848926Phase 2Results posted
• A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedNCT00829166Phase 3Results posted
• Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)CompletedNCT00766116Phase 1/2Results posted
• Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabCompletedNCT00724971Phase 1Results posted
• A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic DiseaseCompletedNCT00679341Phase 2Results posted
• A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00679211Phase 2Results posted
• Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaTerminatedNCT00673153Phase 2Results posted
• CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaCompletedNCT00659425Phase 1Results posted
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT00658814Phase 2Results posted
• A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic LeukemiaTerminatedNCT00587457Phase 1Results posted
• A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell LeukemiaCompletedNCT00586924Phase 1Results posted
• Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00562965Phase 3Results posted
• S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaCompletedNCT00551460Phase 2Results posted
• A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT00509769Phase 2Results posted
• Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00372593Phase 3Results posted

← Immunotoxins overview